Malignant solid tumors
Conditions
Interventions
None listed
Sponsors
National Cancer Center Hospital East
YONSEI University,Seoul,Korea, iTMS Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Age 18 years or older at the registration 2.Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 3.Enrolled in MONSTAR-SCREEN-3 study without withdrawal of consent or refusal for secondary use of information and samples 4.Written informed consent
Exclusion criteria
Exclusion criteria: 1.Active serious infectious disease 2.Life expectancy of less than a few weeks 3.Females during pregnancy or may be pregnant 4.Presence of significant cardiovascular disease, severe hepatic dysfunction, severe renal dysfunction, or poorly controlled diabetes mellitus 5.Any other condition that, in the opinion of the investigator, would make the patient unsuitable for enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between CTC molecular profiling and treatment outcomes, including prognostic implications | — |
Secondary
| Measure | Time frame |
|---|---|
| Association between CTC molecular profiles and multi-omics data from MONSTAR-SCREEN-3 1.Correlation of CTC molecular profiles with clinicopathological factors, including: 2.Overall survival *Progression-free survival *Concordance between tumor tissue and CTC RNA profiles 3.Assessment of anti-metastatic therapeutic targets through CTC analysis 4.Evaluation of Adherent-to-Suspension Transition (AST) factors | — |
Countries
Japan
Contacts
Public ContactTadayoshi Hashimoto
National Cancer Center Hospital East Department for the Promotion of Drug and Diagnostic Development
Outcome results
None listed